Minor physical anomalies may be related to treatment resistance in patients with schizophrenia

Can Uğurpala1, Ertuğ Berberoğlu2, Utku Özkan3

  • 1Vezirkopru State Hospital, Department of Psychiatry, Samsun, Turkey.

PubMed

Insights

Minor physical anomalies (MPA) may indicate treatment resistance in schizophrenia (TRS). Higher MPA scores, particularly in the eye and mouth regions, were observed in TRS patients, suggesting a potential link to treatment outcomes.

Area of Science:

  • Psychiatry
  • Medical Genetics
  • Clinical Psychology

Background:

  • Schizophrenia is a complex mental disorder with varying treatment responses.
  • Minor physical anomalies (MPA) are subtle physical characteristics that have been associated with neurodevelopmental disorders.
  • The relationship between MPA and treatment resistance in schizophrenia (TRS) requires further investigation.

Purpose of the Study:

  • To investigate the association between minor physical anomalies (MPA) and treatment resistance in schizophrenia (TRS).
  • To identify specific MPA patterns or locations linked to treatment resistance.
  • To explore the correlation between MPA scores and symptom severity in TRS.

Main Methods:

  • A cohort of 137 schizophrenia patients and 100 healthy controls were evaluated.
  • The modified Waldrup MPA scale was utilized to assess the presence and severity of MPAs.
  • Patients were categorized into treatment-resistant schizophrenia (TRS) and non-TRS groups for comparative analysis.

Main Results:

  • Thirteen specific MPA items were found more frequently in the schizophrenia group compared to controls.
  • Patients with TRS exhibited significantly higher total MPA scores than non-TRS patients.
  • MPAs in the eye and mouth regions were more prevalent in the TRS group (n=57).
  • Total MPA scores showed a positive correlation with total and positive symptom scores on the Brief Psychiatric Rating Scale-Expanded (BPRS-E) in TRS patients.

Conclusions:

  • Minor physical anomalies may serve as a potential indicator or contributing factor to treatment resistance in schizophrenia.
  • Specific MPA patterns, particularly in the craniofacial region, might be associated with poorer treatment outcomes in schizophrenia.
  • Further research is warranted to elucidate the underlying mechanisms connecting MPA and TRS.

Related Concept Videos

Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
125
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
93
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
68
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
740
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
321
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
165